Cancer Research UK has announced that researchers have launched a clinical trial to develop a breath test that could help to find cancer early, when treatment is more likely to be effective. More: Clinical trial to develop cancer diagnosing breath
read moreBack in mid-2018, AstraZeneca’s Fasenra hit a speed bump as England’s drug cost watchdog recommended it only when GlaxoSmithKline’s rival asthma drug Nucala wasn’t appropriate. But now, the AZ drug is in the fast lane thanks to an expanded recommendation.
read moreIt’s not only Celgene investors who are set for a big payoff with this week’s $74 billion sale to Bristol-Myers Squibb. Thanks to brand-new severance agreements inked days ahead of the deal announcement, its top executives could reap hefty gains,
read moreA host of companies are developing regenerative treatments that lean on stem cells. Seeing an opportunity, Japan’s Fujifilm will build a U.S. stem cell manufacturing facility not only for its own efforts but also as a CDMO. More: Fujifilm plans
read moreBristol-Myers Squibb executives said merging with Celgene delivers six near-term launches—with $15 billion in peak sales potential—into their hands. With them, the company could vault ahead of Roche to be the world’s biggest cancer drug maker. But they won’t fill
read moreBuilt on an existing partnership, Celgene contributes to Antengene’s $120 million series B; Otsuka teams up with Click Therapeutics over digital medicine; Chinese firms MabSpace and HJB merge to create a new biologics specialist; and more. More: FiercePharmaAsia—Celgene invests in
read more© 1994 - 2026 B.M. Pharmaceuticals